Alnylam Pharmaceuticals (ALNY) Cost of Revenue (2018 - 2026)

Alnylam Pharmaceuticals' Cost of Revenue history runs 9 years deep, the most recent figure standing at $207.5 million for Q1 2026.

• Quarterly Cost of Revenue rose 195.68% year-over-year to $207.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $814.5 million (up 152.89% YoY) and the FY2025 annual result came in at $677.2 million, up 120.93% from the prior year.
• Cost of Revenue was $207.5 million for Q1 2026 at Alnylam Pharmaceuticals, down from $267.7 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $267.7 million in Q4 2025 and bottomed at $23.5 million in Q1 2022.
• A 5-year average of $94.1 million and a median of $72.0 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2024 — Cost of Revenue fell 10.71% — and 2026, when it soared 195.68%.
• Alnylam Pharmaceuticals' Cost of Revenue stood at $46.2 million in 2022, then jumped by 55.88% to $72.0 million in 2023, then surged by 42.62% to $102.6 million in 2024, then soared by 160.81% to $267.7 million in 2025, then declined by 22.49% to $207.5 million in 2026.
• Business Quant data shows ALNY's Cost of Revenue at $207.5 million in Q1 2026, $267.7 million in Q4 2025, and $197.2 million in Q3 2025.